Introduction {#s1}
============

In spite of promising advances in antipsychotic treatment, nonadherence to medication remains a common problem in patients suffering from schizophrenia that is largely independent of the type (first vs new generation) or the formulation (oral vs long-acting injectable) of drugs ([@CIT0013]). Most experts define full adherence as taking 80% or more of the prescribed medication and accordingly, about 50% of patients have been reported to be partially or nonadherent ([@CIT0029]). Next to poor insight into the illness, negative attitudes toward medication and adverse effects of antipsychotics ([@CIT0002]), lack of social support, cognitive deficits, and a poor therapeutic alliance ([@CIT0001]) have been shown to be strong predictors for nonadherence, which, in turn, is associated with an increased risk of relapse, rehospitalization, and antipsychotic treatment resistance on one hand and with substance use, violence, arrests, suicide attempts, and impaired long-term functioning on the other ([@CIT0012]).

Depending on the different assessment methods used, reported average adherence rates for schizophrenia patients vary widely, that is, between 10 and 90% ([@CIT0024]). Subjective methods like self-reports and physician reports are most commonly used ([@CIT0029]); however, they frequently underestimate the degree of nonadherence ([@CIT0024]). Using objective methods like pill counting, electronic monitoring, or measuring plasma levels may enhance the chance of detecting adherence problems, but none of these methods can reflect the dosage actually ingested by the patient.

To expand on previous research, the current study aimed to investigate the correlation between simultaneously applied subjective and objective measures of medication adherence. To this end, schizophrenia patients starting monotherapy with a new-generation antipsychotic drug (NGA) in a naturalistic treatment setting were prospectively followed up for 3 months. Using a self-report questionnaire, we assessed the patients' subjective response and attitudes toward medication as an indirect indicator of adherence and investigated whether it is related to the ratio of the observed vs expected plasma levels of the NGA. This approach was chosen to account for inter- and intra-individual variability in drug levels and to provide a rough approximation of the dosage actually ingested. In addition, we investigated the possible influence of antipsychotic-induced side effects in this context.

Methods {#s2}
=======

In- and outpatients fulfilling the diagnostic criteria for schizophrenia spectrum disorders according to ICD-10 between the ages of 18 and 65 years were included into a prospective, naturalistic study after having signed written informed consent in accordance with the local ethics committee. They did not suffer from any other axis I disorders, including substance use. Diagnoses were confirmed using chart information and reports from clinicians who had treated these patients. Patients who had been pretreated with antipsychotics and in whom a switch was indicated because of insufficient efficacy or intolerance underwent a washout period of 3 to 5 days. Taking more than one antipsychotic or treatment with a long-acting injectable antipsychotic were exclusion criteria. Antipsychotics were chosen by the treating psychiatrists, dosing followed clinical needs. Benzodiazepines were permitted to treat agitation, anxiety, or sleep disturbances and biperiden/propranolol for extrapyramidal symptoms and akathisia.

At baseline, sociodemographic and clinical data were obtained. Psychopathology was rated by means of the Positive and Negative Syndrome Scale (PANSS; [@CIT0016]). Follow-up visits were conducted after 2, 4, and 12 weeks of treatment. Patients were asked to fill out the 30-item version of the Drug Attitude Inventory (DAI; [@CIT0014]). A psychiatrist belonging to a trained schizophrenia research team conducted the PANSS rating and quantified side effects using the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale ([@CIT0017]). The relationship between PANSS data and plasma levels will be the subject of a future report.

The DAI assesses the patients' subjective response to antipsychotics and their attitudes toward medication. It is divided into 7 factors: (1) subjective positive feelings related to antipsychotics, (2) subjective negative feelings attributed to the drugs, (3) health/illness-dependent drug intake: patients' model of health, (4) patients' confidence in physician, (5) control: patients' attitudes toward the locus of control in taking medication, (6) prevention: patients' belief in the effect of antipsychotics in forestalling relapse, and (7) harm: patients' concerns with potential toxic effects. The raw subscores of the DAI were converted to a range from 0 to 100 by linear transformation. In addition, a compliance subscore ranging from 0 to 10 was calculated according to the instructions of the developers.

The UKU Side Effect Rating Scale comprises a total of 48 symptoms arranged into 4 groups: psychic, neurological, autonomic, and other side effects. Each symptom is scored on a severity scale from 0 to 3, and the rater assesses whether the report is best attributed to a side effect (rated as improbable, possible, or probable) or related to the disease. Adverse effects with scores ≥1 on any UKU item and a causal relationship of possible or probable were considered as antipsychotic-induced side effects.

At each follow-up visit, a blood sample was taken, and the concentration of the antipsychotic medication in the blood plasma was measured by the ISO 9001-certified psychiatric laboratory using high performance liquid chromatography-tandem mass spectrometry. Blood sampling was conducted before breakfast and before the morning medication, usually at around 8 [am]{.smallcaps}. The expected plasma level of the speciﬁc antipsychotic medication the patient received was calculated using AutoKinetic®, version 3.4 ([@CIT0027]). This software is a Microsoft Excel-based pharmacokinetic simulation program developed by Dr. Stefan W. Toennes at the Institute of Legal Medicine at the Goethe University, Frankfurt/Main, Germany and can be obtained together with a user's manual directly from the author of Autokinetik (toennes\@em.uni-frankfurt.de). Autokinetik allows the calculation of individual expected plasma concentration levels for any medication, has been recommended for therapeutic drug monitoring (TDM; [@CIT0008]), and has even been successfully used to model brain and plasma levels under animal experimental conditions ([@CIT0005]). The required data are the patient's body weight, the period of time to be calculated, and the exact treatment regimen (ie, the prescribed dose and time of intake). In addition, the following pharmacokinetic data are entered: volume of distribution, t-max (= time required for the antipsychotic drug to reach its peak \[ie, maximum\] concentration), terminal elimination half-life, and bioavailability. To emphasize, the advantage of Autokinetic® over more general pharmacokinetics software or equations given in pharmacology textbooks (e.g., [@CIT0003]) is that each dose administered and each time of intake are considered in the calculation of the expected values, allowing for a precise prediction of the expected values at all imaginable doses and dosing intervals. When calculating values on the basis of known doses and pharmacokinetics data taken, for example, from standard pharmacology textbooks and comparing these values with the values calculated by Autokinetic®, a perfect match is obtained (not shown).

Pharmacokinetic data of each drug were obtained from the psychiatric laboratory. The difference between the half-life of olanzapine in males (32 hours) and females (37 hours) was considered in the calculations. The expected plasma level concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, were separately calculated and added. As there exists a large range in the half-life of clozapine (6--26 hours), a value of 12 hours was used for the calculations.

The expected plasma level concentrations used for statistical analysis were steady-state values. However, if the blood sample was taken before steady state had been reached due to changes in medication dosage days prior to blood sampling, we took the expected blood plasma level value on the day of blood sampling, which was calculated using AutoKinetic®. To account for inter- and intra-individual variability, ratios of observed vs expected plasma levels ranging from 0.5 to 2 were considered as normal, whereas ratios ranging from 0 to 0.499 were considered as too low and ratios \>2 as too high. A too-low ratio means that the expected plasma level is higher than the observed plasma level of the antipsychotic drug measured, indicating suboptimal adherence and/or faster-than-average elimination of the medication. A too-high ratio, in turn, means that the expected plasma level is lower than the observed plasma level, indicating that lower-than-average elimination of the medication and/or overadherence, that is, nonprescribed surplus intake by the patient ([@CIT0032]; [@CIT0008]).

Analysis of Data and Statistical Methods {#s3}
----------------------------------------

Only those patients were included in the statistical analysis for whom both the ratio of observed vs expected plasma levels and the DAI were available for at least 1 of the 3 assessment times (weeks 2, 4, and 12 of treatment).

All statistical analyses were performed using SPSS (version 20). As the majority of the variables involved showed departures from a normal distribution, nonparametric statistical tests were used throughout the analysis. The time course of the ratio and of the DAI was analyzed by means of the Friedman test (comparison of all 3 time points) and the Wilcoxon test (pairwise comparison of time points). The McNemar test was employed to test for significant changes of side effects in the course of time (side effects assessed by the UKU were coded as 0=no, 1=yes). The Spearman rank correlation was used to analyze associations between the subscales of the DAI and the ratio of observed vs expected plasma levels. The same method was also used to analyze associations between the ratio and side effects assessed by the UKU.

All statistical tests were performed at a 5% level of significance. To limit the possibility of a chance finding in the correlation tables and other large sets of variables, these were subjected to a Bonferroni correction (*p*-value multiplied by the number of tests conducted).

Results {#s4}
=======

Sample Characteristics {#s5}
----------------------

Demographic and clinical characteristics of the study sample are summarized in [Table 1](#T1){ref-type="table"}. Data of 93 patients were available for baseline analysis. They had a mean age of 36 years and a mean duration of illness of 7.6 years. About two-thirds of participants were male and baseline symptomatology was mild. All patients started monotherapy with an NGA.

###### 

Patient Characteristics (n=93)

  ----------------------------------- -----------------------
  Age, mean ± SD, years               36.0±10.3
  Gender, N (%), male/female          59 (63.4) / 34 (36.6)
  Duration of illness, mean ± SD, y   7.6±7.3
  PANSS score, mean ± SD              
   Total score                        65.9±19.1
   Positive symptoms                  14.5±5.7
   Negative symptoms                  18.2±6.8
   General symptoms                   33.3±9.4
  Antipsychotic treatment, N (%)      
   Amisulpride                        21 (22.7)
   Aripiprazole                       4 (4.3)
   Clozapine                          13 (14.0)
   Olanzapine                         15 (16.1)
   Quetiapine                         13 (14.0)
   Risperidone                        10 (10.8)
   Sertindole                         2 (2.2)
   Ziprasidone                        15 (16.1)
  ----------------------------------- -----------------------

Abbreviation: PANSS, Positive and Negative Syndrome Scale.

Patients' Attitudes toward Medication over the Course of Time (DAI) {#s6}
-------------------------------------------------------------------

[Table 2](#T2){ref-type="table"} gives an overview of the DAI subscales over the course of time. There were no significant differences between the 3 assessment times for any of the DAI subscales. Overall, patients achieved a relatively high DAI total score (mean value \>75) at all 3 observation times. Furthermore, the subscales "subjective positive feelings," "prevention," and "confidence in physician" showed high mean values, reflecting the patients' rather positive attitude toward medication in general. Accordingly, the subscales "subjective negative feelings," "control," "harm," and "health-/illness dependent drug intake" had relatively low scores, which points to the same direction. Lastly, a high DAI compliance subscore (\>7) was observed.

###### 

DAI: Overview and Change over Time

                                              Assessment Time                               
  ------------------------------------------- ----------------- ------ ------ ------ ------ ------
  DAI total score                             76.9              18.7   77.4   18.2   77.8   76.9
  DAI subjective positive feelings            66.8              33.2   64.2   35.6   67.1   66.8
  DAI subjective negative feelings            22.4              26.1   18.2   23.1   21.1   22.4
  DAI confidence in physician                 92.5              23.1   90.1   27.9   92.2   92.5
  DAI prevention                              92.4              21.7   94.9   18.9   95.6   92.4
  DAI control                                 8.9               25.5   5.6    21.0   3.3    8.9
  DAI harm                                    24.3              35.3   21.9   34.5   20.0   24.3
  DAI health-/illness dependent drug intake   34.9              36.4   34.6   30.5   31.1   34.9
  DAI compliance subscore^\#^ (0--10)         7.45              2.21   7.39   2.10   7.43   2.14

Abbreviation: DAI, Drug Attitude Inventory.

^a^ The number of valid cases differed between the individual subscales of the DAI due to the fact that there were slight differences in the number of missing cases per DAI item.

^b^ Note that except for the DAI compliance subscore which has values ranging from 0 to 10, all subscales have values ranging from 0 to 100.

Ratio of Observed vs Expected Plasma Levels {#s7}
-------------------------------------------

A total number of 218 ratios was available for analysis. Of these, 36.3% had been collected in the inpatient setting. More than one-half of the ratios (50.5%, N=110) were between 0.5 and 2 and thus considered normal, 35.3% (N=77) of the ratios were \<0.5, and 14.2% (N=31) were \>2, which was considered rather too low or too high, respectively.

A ratio of 0, indicating total nonadherence, was observed in only 2 cases. These 2 patients had a ratio of 0 only once, whereas they presented with normal ratios (0.5--2) at the other 2 assessment points. Very large ratios were also rare: 2 values were \>10 and another 4 values \>5.

An overview of the time course of the ratio of observed vs expected plasma levels is given in [Table 3](#T3){ref-type="table"}. Although the mean ratio slightly decreased from 1.14 after 2 weeks to 0.98 after 12 weeks of treatment, this difference did not reach statistical significance.

###### 

Time Course of the Ratio of Observed vs Expected Plasma Levels

  Assessment Time   N    Mean   SD     Median
  ----------------- ---- ------ ------ --------
  Week 2            88   1.14   1.31   0.80
  Week 4            81   1.08   1.48   0.63
  Week 12           49   0.98   0.87   0.65

No significant change over the course of time.

Association between Attitude toward Medication (DAI) and the Ratio of Observed vs Expected Plasma Levels {#s8}
--------------------------------------------------------------------------------------------------------

The associations between DAI subscores and the ratio of observed vs expected plasma levels are shown in [Table 4](#T4){ref-type="table"}. Overall, there was only a small number of significant or trend level correlations. Notably, all significant or near-significant tests yielded an inverse correlation, indicating that higher ratios of observed vs expected plasma levels went along with a less positive drug attitude. This also applied to the DAI compliance score at week 2 and, at a trend level, at week 4. A significant negative correlation with the ratio was also seen for the DAI subscale "confidence in physician" at week 4. Trend-level significance (*p*\<.1) was found for the subscale "subjective positive feelings" at all observation times and for the DAI total score at weeks 2 and 4. None of the significances were retained after Bonferroni correction for multiple testing (*p* ~Bonferroni~ \>.1).

###### 

Correlation between DAI (Sub)Scales and Ratio of Observed vs Expected Plasma Levels

  DAI (sub)scale                          Assessment Time                                      
  --------------------------------------- -------------------------- ------------------------- -----------------------
  Total score                             -0.222^\#^ (*P*=.078)^b^   \- 0.193^\#^ (*P*=.096)   -0.223
  Subjective positive feelings            -0.218^\#^ (*P*=.083)      -0.198^\#^ (*P*=.088)     -0.299^\#^ (*P*=.068)
  Subjective negative feelings            0.041                      -0.037                    -0.012
  Confidence in physician                 -0.029                     -0.268\* (*P*=.017)       -0.022
  Prevention                              0.101                      -0.174                    0.207
  Control                                 -0.040                     0.117                     -0.248
  Harm                                    0.086                      0.168                     -0.160
  Health-/illness dependent drug intake   0.107                      0.091                     0.229
  Compliance subscore                     -0.283\* (*P*=.020)        -0.205^\#^ (*P*=.075)     -0.224

Abbreviation: DAI, Drug Attitude Inventory.

Spearman rank correlation coefficient.

\* *P*\<.05.

^\#^ *P*\<.10 (trend-level significance).

^a^ The number of valid cases differed between the individual DAI subscales as there were slight differences in the number of missing cases per DAI item. Moreover, these numbers were smaller than those in [Table 2](#T2){ref-type="table"}, as the corresponding values of the ratio of observed vs expected plasma level were not always available

^b^ Note that *P*-values were denoted only when significance or trend-level significance was attained

The treatment setting (in- vs outpatient setting) was associated with neither DAI scores (total score and subscores, respectively) nor with the ratios (too low, normal, too high).

Side Effects over the Course of Time {#s9}
------------------------------------

[Table 5](#T5){ref-type="table"} shows the frequency of side effects recorded with a severity level of at least 1 on the UKU Side Effect Rating Scale. Only symptoms that were noted as a possible side effect by the rater and only those that occurred in \>20% of cases are listed.

###### 

The Frequency of Side Effects Recorded with a Severity Level ≥1 on the UKU Side Effect Rating Scale

  Side Effect                         Week 2 N = 82   Week 4 N = 81   Week 12 N =53
  ----------------------------------- --------------- --------------- ---------------
  Concentration difficulties          65.5            50.0            43.4^\*^
  Asthenia                            48.8            51.3            50.9
  Sedation                            31.0            30.9            26.4
  Extrapyramidal side effects^a^      56.6            50.6            41.5
  Weight gain                         24.7            25.6            34.0
  Functional sexual disturbances^b^   30.4            21.5            31.3
  Diminished sexual desire            43.4            48.1            41.5
  Amenorrhea (females)                34.5            22.2            15.4

^\*^ Significantly lower than at week 2 (*P*=.021, McNemar test). Significance is not retained after Bonferroni correction for multiple testing.

^a^ Dystonia, rigidity, hypokinesia/akinesia, hyperkinesia, tremor, akathisia

^b^ Erectile dysfunction, ejaculatory dysfunction, orgastic dysfuntion, dry vagina.

The most common side effect reported at week 2 was concentration difficulties, which decreased over the course of time from 65.5% at week 2 to 43.4% at week 12. This decrease attained statistical significance (*p*=.021); however, significance was not retained after Bonferroni correction. Concentration difficulties, sedation, extrapyramidal side effects, and amenorrhea in female patients consistently decreased, whereas weight gain consistently increased over the course of the study, but not in a statistically significant quantity.

Role of Side Effects on View of the Relation between Attitude toward Medication and Ratio of Observed vs Expected Plasma Levels {#s10}
-------------------------------------------------------------------------------------------------------------------------------

To find out whether side effects assessed by the UKU explain the negative correlations between DAI subscores and the ratio of observed vs expected plasma levels (shown in [Table 4](#T4){ref-type="table"}), we investigated the associations between those UKU items that have consistently been found to affect medication adherence (sedation, weight gain, extrapyramidal side effects, and sexual side effects) and the ratio of observed vs expected plasma levels. However, analysis by Spearman correlation coefficients did not reveal any significant associations between the above-mentioned UKU items and the ratio at any of the 3 observation times.

Discussion {#s11}
==========

To the best of our knowledge, this is the first study considering both observed and expected plasma levels of NGA to measure adherence to medication in patients with schizophrenia. Of note, no consistent correlation between patients' attitude toward drug therapy and the ratio of observed vs expected plasma levels of medication was detected. This is in line with previous studies investigating the relationship between different measures of medication adherence ([@CIT0024]).

Generally, a positive attitude toward medication has been suggested to be an indirect indicator of adherence ([@CIT0014]). In this context, patients who have a good alliance with their doctor have been reported to be more likely to adhere to treatment and achieve better outcomes ([@CIT0004]). Accordingly, very high scores on the DAI subscales "prevention" and "confidence in physician" and a high DAI compliance subscore indicate that adherence to medication was remarkably high in our sample, which would be in contrast to studies that have reported approximately 60% of patients with schizophrenia to be nonadherent early in treatment ([@CIT0021]). A possible explanation for this discrepancy may be that only patients with a generally good attitude toward medication and those who had conﬁdence in their doctors agreed to take part in the study. In addition, adherence is known to be higher among study samples than in routine care ([@CIT0015]). Similar to previous studies, this limits the generalizability of the collected data.

One-half of the patients had ratios of observed vs expected plasma levels ranging from 0.5 to 2, indicating that they had been taking their medication as prescribed. The ratios in the remaining patients were considered as either too low or too high, suggesting an aberrant medication intake and/or that the patients eliminated them faster or more slowly than average. However, these findings should be interpreted with some caution. Due to inter-individual pharmacokinetic differences caused by age, concurrent diseases, concomitant medication, or genetic peculiarities and intra-individual variability caused by lifestyle activities such as smoking and caffeine use, it remains challenging to interpret and generalize the results of TDM ([@CIT0028]; [@CIT0008]). Also, blood sample collection represents a "snapshot in time" ([@CIT0020]). Although AutoKinetic® is a very efficient program in calculating expected plasma levels of different drugs, it does not take into account the different activities of drug metabolizing enzymes. Therefore, plasma levels being lower than the expected result may indicate either that a patient has not been taking the medication as prescribed in the days prior to blood sampling and/or that he/she metabolizes/eliminates the medication faster than average. On the other hand, plasma levels being higher than the expected result may indicate that a patient took the medication shortly before blood sampling, that he/she is a poor metabolizer, and/or that he/she takes more medication than prescribed. Notably, treatment with risperidone allows identification of those patients who have taken their medication shortly before blood sampling by yielding a high risperidone-to-9-hydroxyrisperidone ratio ([@CIT0032]). Concordance of the observed and the expected plasma level may indicate that a patient adheres to drug treatment; however, this result is also found in the case of both suboptimal adherence but slower-than-average elimination or overadherence, ie, surplus intake by the patient, and faster-than-average elimination.

Significant correlations between DAI subscores and the ratio of observed vs expected plasma levels were only found for the DAI compliance subscore at week 2 and for the subscale "confidence in physician" at week 4. In both cases, lower DAI subscores correlated with higher ratios. However, given the weak correlations, it cannot be ruled out that this is a chance finding. Further studies addressing this issue are clearly warranted.

Continuously updated guidelines for the use of plasma level determinations, that is, TDM, including recommended therapeutic blood levels, are available ([@CIT0008]). TDM is based on the assumption that a correlation between plasma levels and therapeutic effects, side effects, and toxicity can be established. Regarding the occurrence of side effects associated with NGAs, positive correlations between therapeutic effect and plasma levels have been demonstrated for amisulpride ([@CIT0025]), aripiprazole ([@CIT0026]), olanzapine ([@CIT0022]), and risperidone ([@CIT0030]; [@CIT0031]). Furthermore, a number of studies have reported on the negative impact of antipsychotic-induced side effects on adherence ([@CIT0006]; [@CIT0019]; [@CIT0007]; [@CIT0013]). In our study, side effects were associated with neither the patients' attitudes toward drug therapy nor the ratio of observed vs expected plasma levels. This is in line with our previous studies ([@CIT0010]; [@CIT0023]; [@CIT0011]) and can be interpreted as the consequence of intensive efforts to actively ascertain side effects and to respond to patients' concerns quickly, which has been shown to improve the therapeutic relationship and thereby indirectly enhance adherence ([@CIT0018]; [@CIT0009]).

The naturalistic design of this study also constitutes a limitation. Patients were aware from the start that the purpose of this study was to evaluate adherence to medication and to compare the different measures with each other. It is therefore probable that patients who were generally adherent were more likely to agree to participate, whereas patients with adherence problems declined to take part. Unfortunately, we did not record the number of patients who refused to participate. In addition, it was not possible to include involuntarily committed patients, who are generally considered as seriously ill, as it is forbidden by law to do so in Austria. This can be seen by the relatively low mean PANSS total score at baseline, which indicates a group of patients with mild symptomatology. Similar to other studies, these factors point to a possible selection bias. On the other hand, the naturalistic design comprising few exclusion criteria and the consideration of both observed and expected plasma levels makes our data relevant for everyday clinical practice. It will be critical to conduct further studies in larger samples involving patients who are less adherent to treatment than those who were included in the current study as well and ideally to focus on single substances or substance classes.

To summarize, the ﬁndings of the current study reaffirm that monitoring adherence to medication remains a challenge in clinical practice. As each method has advantages as well as disadvantages, it is up to the attending psychiatrist to play an active role in identifying and minimizing the factors that may lead to nonadherent behavior and to strengthen those factors promoting adherence in each individual patient.
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